Short Interest in Nuvilex Inc. (NASDAQ:PMCB) Drops By 61.7%

Nuvilex Inc. (NASDAQ:PMCB – Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 79,793 shares, a decrease of 61.7% from the August 15th total of 208,161 shares. Based on an average daily volume of 91,412 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.8% of the company’s shares are sold short.

Nuvilex Price Performance

Shares of PMCB stock traded down $0.01 during trading hours on Tuesday, reaching $0.38. 1,029,205 shares of the stock were exchanged, compared to its average volume of 186,526. The business’s fifty day moving average is $0.56 and its two-hundred day moving average is $0.68. The firm has a market capitalization of $4.10 million, a P/E ratio of -0.13 and a beta of 0.66. Nuvilex has a 12-month low of $0.33 and a 12-month high of $1.51.

Get Nuvilex alerts:

Nuvilex (NASDAQ:PMCB – Get Free Report) last issued its quarterly earnings results on Monday, September 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.48).

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 2nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Read Our Latest Analysis on PMCB

About Nuvilex

(Get Free Report)

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.

Further Reading

• Five stocks we like better than Nuvilex
• Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
• 3 Healthcare Stocks for 3 Stages of Life
• Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
• MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky

Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.